1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 11,200 | 12,400 | 08:39 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Adlai Nortye Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| Do | Adlai Nortye jumps 19% on $150M private equity financing | 1 | Seeking Alpha | ||
| Do | Adlai Nortye raises $150M in oversubscribed private placement | 1 | Investing.com | ||
| Do | Adlai Nortye sichert sich 150 Mio. US-Dollar durch überzeichnete Privatplatzierung | 1 | Investing.com Deutsch | ||
| Do | Adlai Nortye Ltd.: Adlai Nortye Announces $150.0 Million Private Placement Equity Financing | 3 | GlobeNewswire (USA) | ||
| ADLAI NORTYE Aktie jetzt für 0€ handeln | |||||
| 10.04. | Adlai Nortye Ltd. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 01.04. | Adlai Nortye Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 23.02. | XFRA AUFHEBUNG VON AMTS WEGEN IN US00704R1095, CA57778R1001, US5949728530, CA83179X1087 | 682 | Xetra Newsboard | Folgende Geschaefte in der ISIN US00704R1095, Wertpapier-Name: ADLAI NORTYE LTD. SP.ADR, wurden von Amts wegen aufgehoben:Folgende Geschaefte in der ISIN CA57778R1001, Wertpapier-Name: MAX POWER MINING... ► Artikel lesen | |
| 13.02. | H.C. Wainwright upgrades Adlai Nortye stock rating to Buy with $16 target | 1 | Investing.com | ||
| 12.02. | Adlai Nortye Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 12.02. | Adlai Nortye Ltd.: Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations | 197 | GlobeNewswire (Europe) | SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company... ► Artikel lesen | |
| 03.02. | Adlai Nortye Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 03.02. | Adlai Nortye Leaps On Stock Deal | 3 | Baystreet.ca | ||
| 03.02. | Adlai Nortye jumps 25%, raises $140M via private placement | 2 | Seeking Alpha | ||
| 03.02. | Adlai Nortye Ltd.: Adlai Nortye Announces $140.0 Million Private Placement Equity Financing | 211 | GlobeNewswire (Europe) | SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company... ► Artikel lesen | |
| 29.01. | Lucid Capital Markets initiates coverage on Adlai Nortye stock with Buy rating | 8 | Investing.com | ||
| 29.12.25 | Adlai Nortye Stock Rises On Exclusive AN9025 China Licensing Deal With ASK Pharm | 2 | RTTNews | ||
| 29.12.25 | Adlai Nortye vergibt Lizenz für Krebsmedikament in 230-Millionen-Dollar-Deal an ASK Pharm | 13 | Investing.com Deutsch | ||
| 29.12.25 | Adlai Nortye licenses cancer drug to ASK Pharm in $230 million deal | 3 | Investing.com | ||
| 29.12.25 | Adlai Nortye Ltd.: Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China | 475 | GlobeNewswire (Europe) | SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 1,652 | +0,61 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,500 | +1,16 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| EDITAS MEDICINE | 2,840 | -0,35 % | Editas Medicine, Inc.: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,800 | -0,89 % | Sarepta/Roche Duchenne therapy to face new late-stage trial targeting EU nod | ||
| BASILEA | 60,10 | +0,50 % | Basilea Pharmaceutica International Ltd, Allschwil: Basilea-Aktionäre genehmigen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats | Allschwil, 15. April 2026
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 8,921 | -3,76 % | Telix Pharmaceuticals Limited: Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma | MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed with... ► Artikel lesen | |
| REPLIGEN | 108,86 | -1,98 % | Repligen Corporation: Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year... ► Artikel lesen | |
| UNIQURE | 14,520 | +1,68 % | Bronstein, Gewirtz & Grossman, LLC: Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm | New York, New York--(Newsfile Corp. - April 13, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed... ► Artikel lesen | |
| CODEXIS | 1,989 | -7,92 % | CODEXIS, INC. - 8-K, Current Report | ||
| ORUKA THERAPEUTICS | 56,00 | -1,75 % | H.C. Wainwright reiterates Oruka Therapeutics stock rating at buy | ||
| MACROGENICS | 2,860 | -1,38 % | Weekly Buzz: MacroGenics Resumes LINNET; GSK Wins China Nod; FDA Okays Waters Corporation; Neurocrine Biosciences Snaps Up Soleno Therapeutics | THOUSAND OAKS (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., Canada, and China, alongside the lifting of a clinical trial hold by the FDA, collaborations... ► Artikel lesen | |
| OMEROS | 10,500 | -1,41 % | Omeros erhält permanenten J-Code für TA-TMA-Medikament Yartemlea | ||
| SPERO THERAPEUTICS | 2,178 | -4,47 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update | Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025In February, Spero's... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 16,405 | -1,14 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference | KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference, April 15, 2026, at 10:15... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 3,480 | -2,79 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026 | MUC16 is the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other emerging targets
MUC16 is highly and stably expressed in the most... ► Artikel lesen |
ADLAI NORTYE LTD ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 10,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADLAI NORTYE LTD ADR finden Sie auf Wallstreet Online.